JULY 27: PUB MED: A trial involving men with hormone-refractory (advanced) prostate cancer who were treated with Provenge (a cellular immunotherapy product called Sipuleucel-T) had a “survival benefit” and only modest side effects, say the Washington researchers. READ MORE>
The integrated results…demonstrate a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo.
The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.
The most common adverse events associated with treatment were chills, pyrexia (fever), headache, asthenia (physical weakness), dyspnea (shortness of breath), vomiting, and tremor.
What do you think about apoptosis, or programmed cell death, and its relationship to cancer?